| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 1996 American Heart Association, Inc.
Articles |
Endothelin Peptide and Receptors in Human Atherosclerotic Coronary Artery and Aorta
the Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital (C.R.B., A.P.D.) and Papworth Hospital (N.R.B.C.), Cambridge, UK.
Correspondence to Dr A.P. Davenport, Clinical Pharmacology Unit, Box 110, Level 2, F&G Block, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The aim of this study was to determine whether there is an alteration in the distribution or quantity of endothelin (ET) peptide or receptor subtypes in human atherosclerotic arteries. Levels of endogenous ET and big ET-1 detectable by radioimmunoassay in human aorta containing raised atherosclerotic plaques were significantly higher than those in histologically normal tissue (Student's t test, P<.01). Immunohistochemistry revealed ET-like immunoreactivity in endothelial cells lining the vessel lumen, neovascularization, recanalization of organized thrombus, and regions rich in macrophages. Little immunoreactivity was associated with vascular smooth muscle cells (VSMCs). Saturation binding assays with [125I]ET-1 indicated comparable affinities and maximal densities of receptors in the media of diseased and normal coronary arteries. Quantitative autoradiography with subtype-selective radioligands revealed similar small proportions of ETB receptors in the diseased and normal arterial media. In arteries with early and late disease, ETA receptors were localized to medial smooth muscle but were lacking in the VSMCs of the intimal layer, where ETB receptors were absent. ETB receptors were detected on perivascular nerves and lymphoid aggregates. In atherosclerotic arteries, microautoradiography localized ETB receptors to neovascularization and, interestingly, to macrophages. The results of this study indicate that there is an increase in ET and big ET-1 associated with fully developed atherosclerotic plaques. It is likely that this is derived from endothelial cells and macrophages but not VSMCs. ETA receptors predominate in the media of both normal and diseased arteries. ET receptors are deficient in intimal smooth muscle, and ETB receptors, where present, are found on endothelial cells and macrophages.
Key Words: atherosclerosis • endothelin • endothelin A • endothelin B • human artery
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Impairment of endothelial function leading to an imbalance in the production of vasoconstrictor mitogenic factors such as ET and the antimitogenic vasodilator NO is believed to be an initiating factor in atherosclerosis.1 Endothelial cells synthesize the vasoactive peptide ET, which when released appears to act on neighboring vascular receptors in an autocrine or paracrine manner.2 ETB receptors located on endothelial cells may mediate vasodilatation via the release of NO.3 In contrast, stimulation of contractile ETA or ETB receptors situated on VSMCs results in potent vasoconstriction.4 5 ETA receptors predominate in the medial smooth muscle layer of human coronary artery and aorta, both examples of arteries prone to atherosclerosis.6 7 8 Only small and inconsistent constrictions to ETB receptor agonists have been observed in these vessels in vitro.9
As the most potent vasoconstrictor described, ET may be a contributing factor in the vasospasm associated with the atherosclerotic arterial wall.10 Furthermore, at subthreshold concentrations, lower than required for ET-induced contraction, it has been reported to potentiate the response to other vasoconstrictors such as serotonin.11 12
A key event in the development of an atherosclerotic plaque is the formation of a neointima due to proliferation of VSMCs. In common with other vasoconstrictors such as angiotensin II,13 ET has the capacity to promote the proliferation of vascular smooth muscle. In the presence of mitogens such as PDGF, ET is comitogenic for cultured rat VSMCs.14 A potentiating action of ET on neointimal formation after rat carotid artery balloon angioplasty has also been demonstrated.15
The release of ET from endothelial cells is known to be stimulated by a number of factors, including TGFß, thrombin, and interleukin-1.16 Invading macrophages may be another potential source of ET in diseased arteries. In culture, these cells secrete ET,17 and release is enhanced in the presence of oxidized low-density lipoprotein,18 as it is in endothelial cells.19 Additionally, VSMCs in culture release the peptide when stimulated by factors such as angiotensin II, TGFß, and PDGF.20
A significant increase in the concentration of circulating ET in patients with advanced atherosclerosis has been reported previously.21 Likewise, risk factors for atherosclerosis, such as diabetes, hypercholesterolemia, and cigarette smoking, may be associated with elevated plasma ET.22 23 24 It is unknown whether this is due to an increase in the production and release of ET or results solely from endothelial cell damage. Semiquantitative studies suggest that the local ET concentration within atherosclerotic tissue is actually increased.25 Interestingly, more ET-1 mRNA has been detected in arteries containing atherosclerotic lesions obtained at carotid endarterectomy than in normal human aorta.26
Given the possible importance of ET in the pathogenesis of atherosclerosis, the purpose of the present study was to qualitatively and quantitatively examine ET peptide and its receptors in human diseased arteries. The aim was to determine whether atherosclerosis is associated with an alteration in the expression of ET or the receptors that mediate its actions. Quantitative techniques including RIA and quantitative autoradiography were used to determine whether upregulation or downregulation of these proteins occurs in atherosclerotic coronary artery and aorta. Visualization by immunohistochemistry and autoradiography also allowed the distinction between VSMCs found in the neointima and those present in the vasoactive part of the vessel, the media. A spectrum of lesions at different stages of development was studied, ranging from preatherosclerotic to fully developed atherosclerotic plaques.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Materials
Amprep C2 minicolumns, Amerlex-M reagent, Hyperfilm ß-max, 125I microscales, and all radioligands ([125I]ET-1, [125I]PD151242, and [125I]BQ3020 [2000 Ci/mmol]) were from Amersham International. Unlabeled ET-1 was from Novabiochem, BQ3020 was synthesized by solid-phase t-boc chemistry, and PD151242 was synthesized by Dr A.M. Doherty (Parke-Davis Pharmaceutical Research Division). Kodak NTB2 nuclear emulsion, D19 developer, Dektol developer, and fixer were from Eastman-Kodak. Bio-Rad DC reagents were obtained from Bio-Rad Laboratories. The following antibodies were purchased from Dako Corp: swine anti-rabbit immunoglobulins, rabbit PAP, rabbit anti-human von Willebrand factor, and monoclonal mouse anti-human macrophage CD68 PG-M1. Monoclonal anti–
smooth muscle actin was from Sigma Immuno Chemicals. The Vectastain ABC kit was from Vector Laboratories. All other reagents were from Fisons and Sigma.
Tissue Samples
The present study was conducted with local ethical approval. Samples of human cardiac arteries were obtained from the recipient hearts of patients undergoing cardiac transplantation for coronary artery disease, cardiomyopathy, or congenital heart disease, with histologically normal coronary arteries, at Papworth Hospital, UK. Coronary artery samples were taken from 23 different individuals for which the average age was 46±16 years (mean±SEM). Drug therapy included Ca2+ antagonists, vasodilators, angiotensin-converting enzyme inhibitors, diuretics, digoxin, and anticoagulants. Aortic samples were also obtained from patients undergoing pulmonary transplantation or from tissue not subsequently used for transplantation.
The adventitia was removed from arteries used for RIA or saturation binding studies. All arteries were immediately snap-frozen in liquid nitrogen and stored at -70°C. Cryostat sections cut for immunohistochemistry, saturation binding assays, and autoradiography studies were thaw-mounted on slides coated with either gelatin or 3-aminopropyltriethoxysilane.
RIA for Mature ET and Big ET-1
RIA was used to compare the amount of immunoreactive ET and the precursor big ET-1 in diseased and nondiseased aorta. These large arteries were selected for RIA experiments because of the greater mass of tissue available for peptide extraction. Fifteen samples of aorta from 14 patients were classified as to whether they were histologically normal, possessed fatty streaks, or raised atherosclerotic plaques. With the adventitia removed, each sample was ground to a powder in a freezer-mill (Glen Creston Ltd), added to 10 vol of 0.5 mol/L acetic acid/0.01% Triton X-100, and heated in a boiling water bath for 15 minutes. This was followed by centrifugation at 48 000g for 20 minutes at 4°C, and resulting supernatants were applied to activated Amprep C2 minicolumns. The columns were washed with 0.1% trifluoroacetic acid before the elution of bound material with 80% methanol/0.1% trifluoroacetic acid. Resulting extracts were evaporated to dryness before reconstitution in RIA buffer (50 mmol/L sodium phosphate, 0.25% bovine serum albumin, 0.01% Tween-20, and 0.05% sodium azide, pH 7.4).
Antisera raised against the common C-terminus of the mature ETs (ET-1[15-21]) at a dilution of 1:10 000 were used to assay the reconstituted extracts for mature ET. An assay for big ET-1 used antisera against the C-terminus of big ET-1 (big ET-1[31-38]) diluted to 1:20 000 as previously described.27
Tissue extracts were incubated with diluted antisera overnight at 4°C before incubating again with [125I]ET-1 or [125I]big ET-1 (
10 000 cpm per tube) under the same conditions. Amerlex-M reagent was used to separate out bound radioligand, which was then counted. Standard curves constructed for unlabeled ET-1 or big ET-1 over the range 0.5 to 1000 fmol per tube (5x10-12 to 10-8 mol/L) were used to determine the immunoreactivity in each tissue extract.
The sensitivity of detection of this assay has been calculated to be <1.25 fmol per tube, with ED50 values between 20 and 25 fmol per tube. Intra-assay and interassay coefficients of variation for the ET RIA were, respectively, as follows: at 6 fmol per tube, 7.8% and 10.8%; at 30 fmol per tube, 9.7% and 12.9%; and at 350 fmol per tube, 13.3% and 19%. For the big ET-1 RIA, the respective values were as follows: at 6 fmol per tube, 8.5% and 10.7%; at 30 fmol per tube, 4.2% and 6.7%; and at 350 fmol per tube, 15.1% and 14.3% (n=25 and 6, respectively). The ET RIA cross-reacts equally with ET-1, ET-2, and ET-3, with <0.02% cross-reactivity with big ET peptides. The big ET-1 RIA only cross-reacts with big ET-1 and the C-terminal fragment of big ET-1.27
There was no evidence of nonnormality using the Shapiro Francia test; data were analyzed by ANOVA, followed by Student's t test (P<.01).
Immunohistochemistry for Mature ETs
Immunohistochemistry was carried out as previously described28 to visualize the distribution of the mature ET peptides in sections of healthy and diseased vessels. The antisera were raised against the common C-terminus of mature ETs and have been shown by enzyme-linked immunosorbent assays to cross-react with ET-1, ET-2, and ET-3 but have no detectable cross-reactivity with big ET precursors.28 Serial 30-µm slide-mounted vessel sections were fixed in 4% paraformaldehyde (4°C, 30 minutes). After they were washed in 0.1 mol/L PBS and permeabilized with 0.1% Triton X-100, the sections were incubated with 10% swine serum (22°C, 30 minutes) as a blocking step. Excess serum was then removed and replaced with the primary rabbit anti-ET antibodies, initially tested at dilutions of 1/100 to 1/1000 and subsequently used at 1/300. In all cases, an adjacent section was treated with preimmune rabbit serum at the same dilution as a negative control. Sections were incubated with primary antibody at 4°C overnight.
A 10-minute wash period preceded the addition of secondary swine anti-rabbit antibody (1/200, 22°C, 60 minutes). The sections were again washed before incubation with rabbit PAP (1/400, 22°C, 60 minutes). A solution of diaminobenzidine was applied to the washed sections; the appearance of the brown reaction product indicated regions of positive immunostaining. Deionized water was used to stop the reaction, and the sections were dehydrated by passage through an alcohol series and cleared in xylene before mounting.
Positive specificity controls included the demonstration that ET antibodies stained the cytoplasm of endothelial cells from human umbilical vein and artery. Specificity was also tested by preabsorbing ET antibodies with ET-1, ET-2, and ET-3.28 In addition to substituting immune serum with preimmune serum, negative controls included the absence of staining when the antiserum was absorbed with its antigen before incubation with tissue sections. Staining was unaffected when antibodies were absorbed with a range of peptides unrelated to ET, at a concentration of 1 µmol/L, including calcitonin gene-related peptide, atrial natriuretic peptide, bradykinin, neuropeptide Y, human vasoactive intestinal peptide, cholestokinin-4, pentagastrin, somatostatin, substance P, eledoisin, dynorphin A (fragment 1-6), and [Met]enkephalin.
[125I]ET-1 Saturation Binding Studies
The binding of [125I]ET-1 in sections of diseased coronary arteries from three patients with ischemic heart disease was compared with that of three histologically normal coronary arteries. Endothelial cells were removed by gentle rubbing, and consecutive 10-µm-thick cryostat sections were cut longitudinally through the media of the arteries. Slide-mounted sections were incubated with HEPES buffer (pH 7.4) containing increasing concentrations of [125I]ET-1 for 2 hours at 22°C as previously described.29 Nonspecific binding was determined at each concentration by inclusion of unlabeled ET-1 (1 µmol/L). After washing, bound radioactivity was determined by gamma counting. Protein concentrations were calculated using the Bio-Rad DC 96-well microtiter method. Binding data were analyzed using the nonlinear iterative curve-fitting program LIGAND.30
Quantitative Autoradiography
Sections were cut to a 10-µm thickness at different orientations through a range of lesions varying from those with predominantly intracellular lipid to fully established atherosclerotic plaques with necrotic cores. ETA receptors were labeled with the ETA-selective radioligand [125I]PD15124231 ; ETB receptors were labeled with the ETB-selective radioligand [125I]BQ3020.32 Sections were incubated in the same conditions as the binding assays with [125I]ET-1 (100 pmol/L), the ETA-selective radioligand [125I]PD151242 (100 pmol/L), or the ETB-selective radioligand [125I]BQ3020 (300 pmol/L). The concentrations used were calculated to label 30% of receptors according to the dissociation constant of each radioligand.7 Nonspecific binding was defined by incubation of adjacent sections with the corresponding unlabeled ligand (1 µmol/L). After they were washed and dried, the sections were apposed, along with [125I]microscale standards, to Hyperfilm ßmax radiation-sensitive film for 7 days at 22°C.
After development in D19 developer, the film images were quantified using computer-assisted image analysis (Quantimet 920, Cambridge Instruments) as previously described.33
Microautoradiography
For higher resolution autoradiography, labeled sections were immersed in Kodak NTB2 nuclear emulsion in complete darkness and allowed to dry. The sections were exposed at 4°C for 7 days before development with Kodak Dektol developer and fixing.
Histology
In all cases, adjacent sections were stained with hematoxylin and eosin to enable histological examination. For further clarification, sections were also stained for the presence of endothelial cells, human smooth muscle -actin, or macrophages.
Endothelial cell staining was achieved using polyclonal rabbit anti–human von Willebrand factor antibodies (1/1000 dilution) on acetone-fixed sections. The PAP detection system was used as described above for the immunohistochemistry for ET.
A monoclonal mouse anti–human smooth muscle -actin antibody and a monoclonal mouse anti–human macrophage antibody (CD68 PG-M1) were used at dilutions of 1/1000 and 1/50, respectively. Staining with these antibodies was achieved by an avidin biotin system using the Vectastain ABC kit with diaminobenzidine as a substrate.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
RIA
Samples of aorta containing raised atherosclerotic plaques or fatty streaks were obtained from five different individuals each (total, 10 samples). Histologically normal aorta was taken from another four individuals and from a different unaffected region of one of the arteries providing raised plaques.
Levels of mature ET and big ET-1 detectable in the aorta samples are shown in Fig 1
. There was no significant difference between the amounts detectable in nondiseased aorta and tissue with fatty streaks. However, there was a highly significant increase in both big ET-1 and mature ET in aorta containing fully developed raised atherosclerotic plaques (ANOVA followed by Student's t test, P<.01). In all three categories of aorta, the quantity of immunoreactive big ET-1 was similar to that of the mature peptide.
|
Immunohistochemistry
ET-like immunoreactivity was demonstrated in the luminal endothelial cells of histologically normal vessels and in perivascular microvessels, with little seen in the media. In arteries with atherosclerotic disease, ET staining was seen in the endothelial cells lining the remains of the lumen. Positive staining was also observed in the endothelial cells in newly formed microvessels, including neovascularization extending through the media and recanalization at sites of previous thrombosis (Fig 2). Although weak diffuse staining occurred across sections, no strong positive signal was obtainable in the cytoplasm of neointimal smooth muscle cells in any of the arteries studied. Discrete patches of immunoreactivity, visualized in the neointima of some vessels, corresponded to regions of macrophage staining.
|
Saturation Binding Assays
Saturation binding assays demonstrated that [125I]ET-1 binds with high affinity and that Hill coefficients are close to unity in both diseased and histologically normal coronary arteries (Table). The dissociation constants were in the same subnanomolar range, indicating that the affinity of the arterial receptors is unchanged in the atherosclerotic artery. The Bmax values calculated were also comparable in ischemic and nonischemic arteries.
|
Autoradiography
Dense binding of [125I]ET-1 was observed in the vascular smooth muscle of the media of all vessels studied. In complete contrast, the smooth muscle of the neointima was virtually devoid of ET receptors (Fig 3). This was apparent in sections cut in a number of different orientations through vessels. Receptors were lacking in the thickened intima of macroscopically normal arteries, as well as in fatty streaks and fully developed atherosclerotic plaques.
|
In agreement with the [125I]ET-1 images, ETA receptors, although present on the thinned media underlying atherosclerotic plaques, were sparse or undetectable in the neointima. Specific [125I]PD151242 binding demonstrated the presence of ETA receptors in the contractile medial smooth muscle, with comparatively little ETB binding in this region. ETB receptors were completely absent in neointimal smooth muscle. In regions of organized thrombus, microautoradiography revealed ETA receptors on the smooth muscle of recanalization vessels (Fig 4).
|
Quantification of autoradiograms was used to determine whether the number of receptors or the ratio of ETA to ETB in the arterial media correlates with atherosclerotic disease. Similar levels of binding were observed, and there was no statistically significant difference in the proportion of ETB receptors detectable in human coronary arteries with and without atherosclerotic disease (Fig 5).
|
Intense [125I]BQ3020 binding was visible on perivascular ETB receptors localized to adventitial lymphatics, nerves, and periadventitial lymphoids. Discrete clusters of ETB receptors were apparent in longitudinal and transverse sections of the media and neointima of diseased vessels but absent in nondiseased arteries. Endothelial cell staining of adjacent sections produced a superimposable pattern of positivity suggesting that ETB receptors are present on neovascularization.
In some atherosclerotic lesions studied, distinct areas of ETB receptors that were not matched by human smooth muscle -actin or von Willebrand factor staining were demonstrated. These cells with ETB receptors were subsequently identified as macrophages by microautoradiography with hematoxylin and eosin staining and macrophage staining (Fig 6).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The results of the present study demonstrate for the first time in a quantitative manner that there is a significant increase in the amount of ET present in human arteries with fully developed atherosclerosis. The ratio of ET to big ET-1 was similar in diseased and normal aorta, implying that ET upregulation in diseased tissue occurs at the level of gene expression rather than at the ET-converting enzyme. The antisera used to measure the amount of mature ET in the RIA27 and to localize the peptide by immunohistochemistry28 cross-react with ET-1, ET-2, and ET-3, and the precise isoform expressed in human arteries has not been determined. Visualization of the actual distribution of peptide by immunohistochemistry suggests that a significant proportion of the increase in mature ET is due to heightened endothelial production. Evidence is emerging that ET-1 and its precursor are the predominant isoforms in human endothelial cells. For example, ET-1 and big ET-1 were detected in human endothelial cells from the endocardium and umbilical vein after separation by high-performance liquid chromatography and RIA of the resulting fractions. However, ET-2 and ET-3 could not be detected.27
Intense staining for ET was seen in the endothelium of newly formed microvessels associated with atherosclerosis, including neovascularization and recanalization of organized thrombus. It has been suggested that the rich microvasculature of neovascularization may promote localized vasospasm and intramural hemorrhage by providing increased tissue concentrations of vasoconstrictors.34
Increased ET levels could also be traced to the presence of invading macrophages in the intimal layer of some arteries. ET immunoreactivity has also been localized to invading inflammatory cells in coronary artery lesions of patients with crescendo angina.25 Activated leukocytes are known to release a stable vasoconstrictor factor.35 Furthermore, circulating lymphocytes and monocytes from patients with chronic heart failure have been shown to spontaneously release ET; this release was not observed in normal subjects.36
In contrast, little immunoreactive ET was detectable in VSMCs, both in the media and neointima, regions where the cells would be expected to be of the contractile or proliferative phenotypes, respectively. A lack of ET in the media of coronary artery has been previously reported.28 37 Conversely, other studies have described ET immunoreactivity localized to vascular smooth muscle of diseased human arteries.21 25 In addition, cultured VSMCs have the ability to synthesize and secrete ET.20 However, the results of the present study indicate that VSMC-derived ET does not contribute greatly to the increase in immunoreactivity observed here in atherosclerotic aorta.
No significant difference in the amount of ET detectable in normal aorta and in tissue with fatty streaks implies that the concentration of ET is unchanged within the fatty streak. However, if increases are focal in nature, local changes in concentration may have remained undetected when the entire piece of artery was assayed. Therefore, a role for ET in the development of the fatty streak cannot be eliminated on the basis of the present study.
Radiolabeled ET-1 bound with similar affinity to receptors in the media of diseased and nondiseased coronary artery. The difference in Bmax values in these tissues was small, ruling out a large upregulation or downregulation of ET receptors associated with ischemic heart disease. Quantification of autoradiograms also indicated similar densities of receptors in arteries with and without atherosclerosis. Functional studies have indicated that healthy arteries are more sensitive than diseased arteries to low concentrations of ET-1, although the maximal contractile effect was similar.12
Contractile smooth muscle, in the arterial media and in the walls of new vessels in regions of recanalization, contained predominantly ETA receptors. This is consistent with a number of functional studies with human arteries.6 9 An example of species differences is provided by porcine coronary artery, where a significant non-ETA contractile component has been demonstrated.4
In some animal models, an upregulation of ETB receptors has been identified, which is related to high cholesterol diet38 and vascular disease.39 Additionally, a phenotypic change toward ETB receptors has been reported in late-passage rat cultured VSMCs.40 To examine whether such a shift occurs in human vessels, quantitative autoradiography was used to compare the proportions of ETA and ETB receptors in the media of normal and diseased coronary arteries. The results demonstrate that there is no significant change in the proportion of ETB receptors present on medial smooth muscle of the human artery associated with atherosclerotic disease.
The absence of ET receptors in the intimal layer of coronary arteries has been previously reported.8 41 In the present study, this has been observed in the muscular elastic layer of normal arteries and in the neointima of atherosclerotic lesions at all stages of development. These ranged from the early (including areas of intimal thickening with predominantly intracellular lipid) to the advanced (with necrotic lipid core) atherosclerotic plaque. Such findings are consistent with the lack of expression of ETA receptor mRNA detectable in the thickened arterial intima of hypertensive patients.42 It remains to be seen whether ET receptors are actually downregulated in the proliferative VSMC phenotype or whether their absence reflects an undifferentiated state of the cells in the intima. In human cultured VSMCs, the mitogenic effect of ET-1, which correlated with ET receptor density, decreased with increasing population doubling of cells.43 Interestingly, this effect on receptor number and responsiveness did not correlate with the rate of ET secretion by the cells. Cultured rabbit VSMCs have also been demonstrated to downregulate ET receptors when switching to the proliferative phenotype.44 In the study by Kanse et al,43 the ETA antagonist BQ123 completely inhibited [125I]ET-1 binding, and ET-1 induced mitogenesis of cultured human VSMCs. The order of potency of the ET isopeptides (ET-1=ET-2>ET-3) also indicated that the mitogenic effect of ET-1 is mediated by ETA receptors in these cells. Therefore, it is possible that ETA receptors are involved in an initial proliferative response in human VSMCs, but the progression of cells through successive divisions appears to be accompanied by downregulation of the receptors. Perhaps this downregulation accounts for the deficiency of ETA receptors in the intimal layer of human arteries.
Interestingly, ETB receptors were detected on macrophages within atherosclerotic plaques and on aggregates of lymphocytes. Previously, ETB receptors also have been identified on mouse peritoneal macrophages.45 ET has chemoattractant activity for macrophages and stimulates the release of factors such as interleukin-6.46 47 Furthermore, monocytic cells have been reported to increase the vascular contractile potency of ET-1, possibly via the stimulation of monocyte ET receptors.48 Given the importance of these cells in the pathogenesis of atherosclerosis, the significance of ET in their function is intriguing.
ETB receptors were also localized by microautoradiography to endothelial cells of neovascularization extending through the media of diseased arteries. The presence of ETB receptors on these new microvessels may explain the sites reported to be resistant to ETA receptor antagonists in atherosclerotic arteries.49
In previous binding studies with sections of the media of histologically normal aorta, ETB receptors were undetectable.7 However, in other studies with aortic media from patients with ischemic heart disease, a small population of 10% ETB receptors was detected.50 The results of the present study suggest that this small difference is due to endothelial cells of neovascularization and possibly the presence of inflammatory cells in diseased arteries. The endogenous concentration of the potent vasoconstrictor ET is increased in human atherosclerotic arteries. When released from damaged endothelium, it may contribute to the development of atherosclerosis by promoting proliferation of VSMCs. Additionally, by interacting with the ETA receptors, which predominate on human vascular smooth muscle, it could contribute to vasospasm and the events accompanying plaque rupture. Pharmacological intervention in the form of ET receptor antagonists is currently being considered for the treatment of vascular disease.51 A better understanding of the implications of these therapeutic strategies is likely to result from identification of cell types expressing ET and characterization of ET receptors within atherosclerotic plaques.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This study was supported in part by the British Heart Foundation and the Isaac Newton Trust. C.R. Bacon was funded by an MRC studentship during this research. We would like to thank the consultants and theater staff of Papworth hospital for permission to collect human tissue. We are grateful to M. Ashby, Dr C. Plumpton, and Dr F. Russell for technical advice.
Received February 9, 1996; accepted June 14, 1996.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Ohlstein EH, Douglas SA. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Dev Res. 1993;29:108-128.
2.
Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
3.
De Nucci G, Thomas R, D'Orleans-Juste P, Antumes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988;85:9797-9800.
4. Harrison VJ, Randriantsoa A, Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992;105:511-513.[Medline] [Order article via Infotrieve]
5. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci. 1992;13:103-108.[Medline] [Order article via Infotrieve]
6. Godfraind T. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol. 1993;110:1201-1205.[Medline] [Order article via Infotrieve]
7. Bacon CR, Davenport AP. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol. 1996;117:986-992.[Medline] [Order article via Infotrieve]
8. Bacon CR, Cary NRB, Davenport AP. Distribution of endothelin receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 1995;26(suppl 3):S439-S441.
9. Maguire JJ, Davenport AP. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995;115:191-197.[Medline] [Order article via Infotrieve]
10. Kurihara H, Yoshizumi M, Sugiyama T, Yamaoki K, Nagai R, Takaku F, Satoh H, Inui J, Yanagisawa M, Masaki T, Yazaki Y. The possible role of endothelin-1 in the pathogenesis of vasospasm. J Cardiovasc Pharmacol. 1989;13(suppl 5):S132-S137.
11.
Yang Z, Richard V, von Segesser L, Bauer E, Stultz P, Turina M, Luscher TF. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation. 1990;82:188-195.
12. Chester AH, O'Neil GS, Allen SP, Luu TN, Tadjkarimi S, Yacoub MH. Effect of endothelin on normal and diseased human coronary arteries. Eur J Clin Invest. 1992;22:210-213.[Medline] [Order article via Infotrieve]
13.
Gibbons GH, Dzau VJ. The emerging concept of vascular remodelling. N Engl J Med. 1994;330:1431-1438.
14. Weissberg PL, Witchell C, Davenport AP, Hesketh TR, Metcalf JC. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis. 1990;85:257-262.[Medline] [Order article via Infotrieve]
15.
Douglas SA, Louden C, Vickery-Clark LM, Storer BL, Hart T, Feuerstein GZ, Elliott JD, Ohlstein EH. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty: protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res. 1994;75:190-197.
16. Maemura K, Kurihara H, Morita T, Ohhashi Y, Yazaki Y. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology. 1992;38:29-35.
17.
Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990;172:1741-1748.
18. Martin-Nizard F, Houssaini HS, Lestavel-Delattre S, Duriez P, Fruchard J-C. Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. FEBS Lett. 1991;293:127-130.[Medline] [Order article via Infotrieve]
19.
Boulanger CM, Tanner FC, Bea M-L, Hahn AWA, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70:1191-1197.
20. Resink TJ, Hahn AWA, Scott-Burden T, Powell J, Weber E, Buhler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun. 1990;168:1303-1310.[Medline] [Order article via Infotrieve]
21. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.[Abstract]
22. Takahashi K, Ghatei MA, Lam H-C, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in diabetes mellitus. Diabetologia. 1990;33:306-310.[Medline] [Order article via Infotrieve]
23. Bath PM, Martin JF. Serum platelet-derived growth factor and endothelin concentrations in human hypercholesterolaemia. J Intern Med. 1991;230:313-317.[Medline] [Order article via Infotrieve]
24. Haak T, Jungmann E, Raab C, Usadel KH. Elevated endothelin-1 levels after cigarette smoking. Metab Clin Exp. 1994;43:267-269.
25.
Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 1995;91:941-947.
26. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun. 1993;191:1081-1088.[Medline] [Order article via Infotrieve]
27. Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP. Expression of endothelin peptides and mRNA in human heart. Clin Sci. 1996;90:37-46.[Medline] [Order article via Infotrieve]
28. Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992;10:1379-1386.[Medline] [Order article via Infotrieve]
29.
Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA, Davenport AP. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993;72:526-538.
30. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for the characterization of ligand binding systems. Anal Biochem. 1980;107:220-239.[Medline] [Order article via Infotrieve]
31. Davenport AP, Kuc RE, Fitzgerald F, Maguire JJ, Berryman K, Doherty AM. [125I]-PD151242: a selective radioligand for human ETA receptors. Br J Pharmacol. 1994;111:4-6.[Medline] [Order article via Infotrieve]
32. Ihara M, Saeki T, Fukuroda T, Kimura S, Ozaki S, Patel AC, Yano M. A novel radioligand [125I]BQ3020 selective for endothelin (ETB) receptors. Life Sci. 1992;51:47-52.
33. Davenport AP, Beresford IJM, Hall MD, Hill RG, Hughes J. Quantitative autoradiography in neuroscience. In: Van Leeuwen FW, Buijis RM, Pool CW, Pach O, eds. Molecular Neuroanatomy. Amsterdam, Netherlands: Elsevier Science Publishing Co; 1988;3:121-145.
34. Barger AC, Beeuwkes R, Lainey LL, Silverman KJ. Hypothesis: vaso vasorum and neovascularization of human coronary arteries: a possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984;310:175-177.[Medline] [Order article via Infotrieve]
35. Mugge A, Lopez JAG, Heistad DD, Lichtlen PR. Vasoconstriction in response to activated leukocytes: implications for vasospasm. Eur Heart J. 1993;14(suppl I):87-92.
36. Krum H, Itescu S. Spontaneous endothelin production by circulating mononuclear cells from patients with chronic heart failure but not from normal subjects. Clin Exp Pharmacol Physiol. 1994;21:311-313.[Medline] [Order article via Infotrieve]
37. Opgaard OS, Adner M, Gulbenkian S, Edvinsson L. Localization of endothelin immunoreactivity and demonstration of constrictory endothelin-A receptors in human coronary arteries and veins. J Cardiovasc Pharmacol. 1994;23:576-583.[Medline] [Order article via Infotrieve]
38.
Elshourbagy NA, Korman DR, Wu HL, Sylvester DR, Lee JA, Nuthalaganti P, Bergsma DJ, Kumar CS, Nambi P. Molecular characterization and regulation of the human endothelin receptors. J Biol Chem. 1993;268:3873-3879.
39.
Azuma H, Hamasaki H, Niimi Y, Terada T, Matsubara O. Role of endothelin-1 in neointima formation after endothelial removal in rabbit carotid arteries. Am J Physiol. 1994;267:H2259-H2267.
40.
Eguchi S, Hirata Y, Imai T, Kanno K, Marumo F. Phenotypic change of endothelin receptor subtype in cultured rat vascular smooth muscle cells. Endocrinology. 1994;134:222-228.
41. Power RF, Wharton J, Zhao Y, Bloom SR, Polak JM. Autoradiographic localization of endothelin-1 binding sites in the cardiovascular and respiratory systems. J Cardiovasc Pharmacol. 1989;13(suppl 5):S50-S56.
42.
Hasegawa K, Fujiwara H, Doyama K, Inada T, Ohtani S, Fujiwara T, Hosoda K, Nakao K, Shigetake S. Endothelin-1–selective receptor in the arterial intima of patients with hypertension. Hypertension. 1994;23:288-293.
43. Kanse SM, Wijelath E, Kanthou C, Newman P, Kakkar VV. The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density. Lab Invest. 1995;72:376-382.[Medline] [Order article via Infotrieve]
44. Serradeil-Le Gal C, Herbert JM, Garcia C, Boutin M, Maffrand JP. Importance of the phenotypic state of vascular smooth muscle cells on the binding and the mitogenic activity of endothelin. Peptides. 1991;12:575-579.[Medline] [Order article via Infotrieve]
45. Kishino J, Hanasaki K, Kato T, Arita H. Endothelin-induced intracellular Ca2+ mobilization through its specific receptors in murine peritoneal macrophages. FEBS Lett. 1991;280:103-106.[Medline] [Order article via Infotrieve]
46. Helset E, Sildnes T, Seljelid R, Konopski ZS. Endothelin-1 stimulates human monocytes in vitro to release TNF-alpha, IL-1beta and IL-6. Mediat Inflammation. 1993;2:417-422.
47. Helset E, Sildnes T, Konopski ZS. Endothelin-1 stimulates monocytes in vitro to release chemotactic activity identified as interleukin-8 and monocyte chemotactic protein-1. Mediat Inflammation. 1994;3:155-160.
48. Magazine HI, Andersen TT, Bruner CA, Malik AB. Vascular contractile potency of endothelin-1 is increased in the presence of monocytes or macrophages. Am J Physiol. 1994;266(Heart Circ Physiol 35):H1620-H1625.
49. Dashwood MR, Allen SP, Luu TN, Muddle JR. The effect of the ETA receptor antagonist, FR139317, on [125I]ET-1 binding to the atherosclerotic human coronary artery. Br J Pharmacol. 1994;112:386-389.[Medline] [Order article via Infotrieve]
50. Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA subtype. Br J Pharmacol. 1995;114:1110-1116.[Medline] [Order article via Infotrieve]
51. Shiosaki K. Endothelin receptor antagonists. Exp Opin Ther Patents. 1994;4:1361-1365.
This article has been cited by other articles:
 |
|
 |
|
  D. W. Anggrahini, N. Emoto, K. Nakayama, B. Widyantoro, S. Adiarto, N. Iwasa, H. Nonaka, Y. Rikitake, Y. Y. Kisanuki, M. Yanagisawa, et al. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation Cardiovasc Res, April 1, 2009; 82(1): 143 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P.J. Halcox, K. R.A. Nour, G. Zalos, and A. A. Quyyumi Endogenous Endothelin in Human Coronary Vascular Function: Differential Contribution of Endothelin Receptor Types A and B Hypertension, May 1, 2007; 49(5): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Johnstrom, J. H. F. Rudd, H. K. Richards, T. D. Fryer, J. C. Clark, P. L. Weissberg, J. D. Pickard, and A. P. Davenport Imaging Endothelin ETB Receptors Using [18F]-BQ3020: In Vitro Characterization and Positron Emission Tomography (MicroPET). Experimental Biology and Medicine, June 1, 2006; 231(6): 736 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Jackson, K. Barnes, S. Homer-Vanniasinkam, and A. J. Turner Expression and localization of human endothelin-converting enzyme-1 isoforms in symptomatic atherosclerotic disease and saphenous vein. Experimental Biology and Medicine, June 1, 2006; 231(6): 794 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Maguire, K. E. Wiley, R. E. Kuc, V. E. A. Stoneman, M. R. Bennett, and A. P. Davenport Endothelin-Mediated Vasoconstriction in Early Atherosclerosis Is Markedly Increased in ApoE-/- Mouse but Prevented by Atorvastatin. Experimental Biology and Medicine, June 1, 2006; 231(6): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Sutherland, M. I. Nataatmadja, P. J. Walker, L. Cuttle, R. B. Garlick, and M. J. West Vascular Remodeling in the Internal Mammary Artery Graft and Association With In Situ Endothelin-1 and Receptor Expression Circulation, March 7, 2006; 113(9): 1180 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rodriguez-Vita, M. Ruiz-Ortega, M. Ruperez, V. Esteban, E. Sanchez-Lopez, J. J. Plaza, and J. Egido Endothelin-1, via ETA Receptor and Independently of Transforming Growth Factor-{beta}, Increases the Connective Tissue Growth Factor in Vascular Smooth Muscle Cells Circ. Res., July 22, 2005; 97(2): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Lee, B. R. Wamhoff, L. C. Katwa, H. K. Reddy, D. J. Voelker, J. L. Dixon, and M. Sturek Increased Endothelin-Induced Ca2+ Signaling, Tyrosine Phosphorylation, and Coronary Artery Disease in Diabetic Dyslipidemic Swine Are Prevented by Atorvastatin J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 132 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Herrmann, P. J. Best, E. L. Ritman, D. R. Holmes Jr, L. O. Lerman, and A. Lerman Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1555 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Quehenberger, M. Exner, R. Sunder-Plassmann, K. Ruzicka, C. Bieglmayer, G. Endler, C. Muellner, W. Speiser, and O. Wagner Leptin Induces Endothelin-1 in Endothelial Cells In Vitro Circ. Res., April 5, 2002; 90(6): 711 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ihling, T. Szombathy, B. Bohrmann, M. Brockhaus, H. E. Schaefer, and B. M. Loeffler Coexpression of Endothelin-Converting Enzyme-1 and Endothelin-1 in Different Stages of Human Atherosclerosis Circulation, August 21, 2001; 104(8): 864 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Taner, S. R. Severson, P. J. M. Best, A. Lerman, and V. M. Miller Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia J Appl Physiol, March 1, 2001; 90(3): 816 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. MacCarthy, N. C. Pegge, B. D. Prendergast, A. M. Shah, and P. H. Groves The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone J. Am. Coll. Cardiol., January 1, 2001; 37(1): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Thorin, M. Lucas, P. Cernacek, and J. Dupuis Role of ETA receptors in the regulation of vascular reactivity in rats with congestive heart failure Am J Physiol Heart Circ Physiol, August 1, 2000; 279(2): H844 - H851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Scotland, P. J.T. Vallance, and A. Ahluwalia Endogenous factors involved in regulation of tone of arterial vasa vasorum: implications for conduit vessel physiology Cardiovasc Res, June 1, 2000; 46(3): 403 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gobel, C. Ihling, J. Dentz, H. E. Schaefer, A. M. Zeiher, and G. Fraedrich Increased tissue endothelin-1-like immunoreactivity in the internal mammary artery of patients with diabetes or hypercholesterolemia modulates the graft flow in the peri-operative period Eur. J. Cardiothorac. Surg., October 1, 1999; 14(4): 367 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D. Russell and A. P. Davenport Evidence for Intracellular Endothelin-Converting Enzyme-2 Expression in Cultured Human Vascular Endothelial Cells Circ. Res., April 30, 1999; 84(8): 891 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D. Russell, J. N. Skepper, and A. P. Davenport Human Endothelial Cell Storage Granules : A Novel Intracellular Site for Isoforms of the Endothelin-Converting Enzyme Circ. Res., August 10, 1998; 83(3): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. McKenna, S. E. Burke, T. J. Opgenorth, R. J. Padley, L. J. Camrud, A. R. Camrud, J. Johnson, P. J. Carlson, A. Lerman, D. R. Holmes Jr, et al. Selective ETA Receptor Antagonism Reduces Neointimal Hyperplasia in a Porcine Coronary Stent Model Circulation, June 30, 1998; 97(25): 2551 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Thorin, P. Cernacek, and J. Dupuis Endothelin-1 Regulates Tone of Isolated Small Arteries in the Rat : Effect of Hyperendothelinemia Hypertension, April 1, 1998; 31(4): 1035 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shichiri, S. Adachi, J. M. Sedivy, F. Marumo, and Y. Hirata Biphasic Regulation of the Preproendothelin-1 Gene by c-myc Endocrinology, November 1, 1997; 138(11): 4584 - 4590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hasdai, V. Mathew, R. S. Schwartz, L. A. Smith, D. R. Holmes Jr, Z. S. Katusic, and A. Lerman Enhanced Endothelin-B-Receptor–Mediated Vasoconstriction of Small Porcine Coronary Arteries in Diet-Induced Hypercholesterolemia Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2737 - 2743. [Abstract] [Full Text]
|
|
|
|
|
|
P. Quehenberger, M. Exner, R. Sunder-Plassmann, K. Ruzicka, C. Bieglmayer, G. Endler, C. Muellner, W. Speiser, and O. Wagner Leptin Induces Endothelin-1 in Endothelial Cells In Vitro Circ. Res., April 5, 2002; 90(6): 711 - 718. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||